Human PLA2G7 (诊断原料,心肌标志物）

Recombinant Human PLA2G7 

 

Catalog #:  DC624        Derived From: Human Cells   

 

Description:

Recombinant Human PAF-AH/PLA2G7 (C-6His) is produced by Mammalian expression system and the target gene encoding Phe22-Asn441 is expressed with a 6His tag at the C-terminus.

Accession:  AAH38452.1

Names(Known as):Platelet-Activating Factor Acetylhydrolase; PAF Acetylhydrolase; 1-Alkyl-2-Acetylglycerophosphocholine Esterase; 2-Acetyl-1-Alkylglycerophosphocholine Esterase; Group-VIIA Phospholipase A2; gVIIA-PLA2; LDL-Associated Phospholipase A2; LDL-PLA(2); PAF 2-Acylhydrolase; PLA2G7; PAFAH

 

Quality Control:

Mol Mass:  48.8kDa                     AP Mol Mass:  50-65kDa, reducing conditions

Purity:  Greater than 95% as determined by reducing SDS-PAGE.

Bioactivity-BLI:

 

Loaded Human Lp-PLA2 Antibody (4E11)-mFc(Cat#DA056) on AMC Biosensor, can bind Human PLA2G7-His(Cat#DC624) with an affinity constant of 0.015 nM as determined in BLI assay.		Loaded Human Lp-PLA2 Antibody (7G5)-mFc(Cat#DA057) on AMC Biosensor, can bind Human PLA2G7-His(Cat#DC624) with an affinity constant of 0.55 nM as determined in BLI assay.

 

Formulation:

Supplied as a 0.2 μm filtered solution of 50mM NaAc, 150mM NaCl, 10% Glycerol, pH 5.0.

 

Shipping:

The product is shipped on dry ice pack. Upon receipt, store it immediately at the temperature listed below.

 

Storage:

Reconstituted protein solution should be stored at ≤ -20°C.

 

Purification: 

Affinity purification chromatography.

 

Immunoreactivity: 

N.A.

 

Application:

Immunogen, calibrator or standard.

 

Background:

Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB hydrolase superfamily and Lipase family and catalyzes the degradation of platelet-activating factor to biologically inactive products. PAFAH is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. PAFAH has been implicated in the development of atherosclerosis and has also been identified as a marker for cardiac disease. PAFAH might have a major physiologic effect in the presence of inflammatory bodily responses. PAFAH alters the action of PAF by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. PAFAH has specificity for substrates with a short residue at the sn-2 position.

 

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY